TIL Revenue and Competitors
Estimated Revenue & Valuation
- TIL's estimated annual revenue is currently $150M per year.
- TIL's estimated revenue per employee is $302,470
- TIL has 496 Employees.
- TIL grew their employee count by 4% last year.
TIL Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is TIL?
TIL Limited is a leading provider of world-class infrastructure equipment in India, in alliance with global technology leaders. The Company designs, manufactures and markets a comprehensive range of material handling, lifting, port equipment and road building solutions, with integrated customer support and after sales service. Headquartered in Kolkata, capital city of West Bengal, India, TIL has regional offices in Kolkata, Delhi, Mumbai and Chennai, with a network of branches and area offices across the country. TIL has two factories in Eastern India - a fully integrated plant at Kamarhatty, Kolkata, that is the only purpose-built mobile crane-manufacturing facility in India, certified under national and international standards, and a state-of-the-art ERP-enabled factory at Kharagpur, West Bengal, which is engaged in the manufacture of reach stackers and crushing & screening solutions. Global technology partners include the Manitowoc Crane Group, the Hyster-Yale Group, Astec Inc. and PACECO Corp. Products offered by TIL include - an extensive range of truck & truck mounted cranes (25 - 100 T), rough terrain cranes (20 - 135 T), all-terrain cranes (60 - 450 T), industrial cranes (upto 20 T), pick & carry cranes (15 T), crawler cranes, RTG cranes, reach stackers, container handlers, forklifts, hot mix asphalt plants, crushing & screening solutions.keywords:N/A
Number of Employees
Employee Growth %
The company hopes to extend the benefit of TIL therapies to solid tumors by selecting and manufacturing the most potent tumor-reactive T-cells...
Published: Apr 25, 2022. Collaboration focused on developing novel strategies for tumor-reactive T-cell selection in Turnstone's TIL therapy candidates...
Talking Friars Ep. 154: NO(more)LA 'til June. Sorry Dodgers fans but this felt like rivalry. By Ben Fadden Ben_Fadden Apr 24, 2022,...
LN-145, a tumor-infiltrating lymphocyte (TIL) therapy, demonstrated promising response rates and an acceptable safety profile in patients with ...
Wanderers forward Nick Freeman has signed a two-year extension to his contract, keeping him at Adams Park until June 2022. The 23-year-old ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|